Navigation Links
Nucletron Spotlights Innovations During ESTRO29
Date:9/10/2010

Nucletron Spotlights Innovations During ESTRO29 -- VEENENDAAL, The Netherlands, September 10, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, New Products & Services, Trade Show News Click to view news release full screen  

Nucletron Spotlights Innovations During ESTRO29

 

VEENENDAAL, The Netherlands, September 10, 2010 /PRNewswire/ --

- Exciting New Solutions for Precision Cancer Treatment on Display During ESTRO29 in Barcelona, Spain

Nucletron, a leading provider of state of the art radiotherapy solutions for cancer treatment, today announced a large number of exciting innovations for precise cancer treatment that will be in the spotlight during ESTRO29 in Barcelona. The company will be showcasing the latest developments in cancer treatment solutions for both brachytherapy and external beam.

The complete program for prostate brachytherapy

Nucletron Prostate Solutions is the first complete program for prostate brachytherapy, integrating state-of-the-art Oncentra software and high-class brachytherapy equipment. Next to years of evidence confirming favorable cure rates, these advanced solutions shorten overall treatment times, while reducing risks of impotence and incontinence. Available for two treatment types - Oncentra(R) Seeds for permanent low dose rate (LDR) seeds implantation and Oncentra(R) Prostate for high dose rate (HDR) - it offers the best choice of treatment for many prostate cancer patients.

Breast brachytherapy: See what you treat, treat what you see

AccuBoost(TM) is the first technology to use HDR brachytherapy treatment of breast cancer in a non-invasive way, utilizing real-time mammography imaging to accurately target the radiation dose directly to the lumpectomy site. AccuBoost can be delivered either prior to or after the main external beam portion of a woman's breast irradiation treatment.

Pioneering developments in gynecological brachytherapy

Whether you use CT, MR or any other imaging modality, Nucletron can offer a suitable applicator for gynecological brachytherapy. The newest in our range of applicators are the Multichannel Vaginal Cylinder for asymmetrical and advanced vaginal and cervical tumors, and the Rotterdam Cervix Applicator, designed for fast and reproducible treatments. These two applicators give ultimate precision in gynecological brachytherapy.

Optimal speed and precision in treatment planning

Oncentra(R) 4.0 is the newest version of Nucletron's multi-modality treatment planning system for brachytherapy and external beam treatment. Oncentra v4.0 is the first ever platform to use GPU technology to increase plan accuracy and reduce planning times from hours to minutes, especially for VMAT calculations. New Oncentra Brachy features, such as applicator modeling, library plans and output manager, are specially developed to make brachytherapy treatment planning easier and faster.

Flexitron numbers talk

The Flexitron afterloader takes brachytherapy to a new level. It helps to shorten preparation time and reduces the chance of human errors with its straightforward Absolute Source Positioning. It sets a new safety benchmark, with features like the precise source drive. It's not just words, Flexitron's numbers talk and improve safety!

Visit Nucletron during ESTRO29 at booth 170 to find more information on the latest innovations in precision cancer treatment, and to receive a demo. Visit http://www.nucletron.com/estro29 for more information.

About Nucletron

Nucletron provides state of the art radiotherapy solutions for cancer treatment that meet the evolving needs of patients, their caregivers and healthcare professionals around the world. Nucletron has unmatched global leadership in brachytherapy, a very precise, highly effective and well-tolerated treatment option for healthcare providers, tailored to the needs of individual patients. We work with clinical teams to constantly improve and develop an innovative portfolio of integrated products, software and services that assures excellent patient outcomes. Headquartered in Veenendaal, The Netherlands, Nucletron employs more than 500 employees, with offices in 15 countries, and products available in more than 100 countries around the world. Please visit http://www.nucletron.com to learn more about our healthcare solutions.

http://www.nucletron.com


'/>"/>
SOURCE Nucletron
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Nucletron Announces Market Release of First Commercially Available Software to Review and Share Dicom-Based Treatment Plans for Radiotherapy
2. Nucletron Announces 2008 Results
3. Nucletron Releases Comprehensive Film-and Volume-Based Planning System for Wide Variety of Brachy Solutions
4. Dutch Medical Equipment Producer Nucletron Strengthens Leading Position in Cancer Radiation Therapy Market
5. Inverness Medical Innovations Features Innovative TB Diagnostic - Clearview(R) TB ELISA at AIDS 2008
6. Inverness Medical Innovations to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 9, 2008
7. Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
8. Inverness Medical Innovations to Attend the Goldman Sachs Diagnostics Conference on September 18, 2008
9. Inverness Medical Innovations to Present at the UBS Global Life Sciences Conference on September 22, 2008
10. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET October 29, 2008 to Discuss Third Quarter 2008 Results
11. Inverness Medical Innovations Announces Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)...  ArmaGen, Inc., a privately held biotechnology company ... neurological disorders, today reported preliminary evidence of cognitive ... investigational therapy for the treatment of Hurler and ... or MPS I). The initial results from an ... at the 13 th annual WORLD Symposium ...
(Date:2/16/2017)... , February 16, 2017 ... infusion of innovative telemedicine application, new and leading ... are experiencing a boom worldwide. The healthcare sector ... of technologies, services and new therapies for companies ... (TSX-V: RHT), Cellectar Biosciences, Inc. (NASDAQ: ...
(Date:2/16/2017)... (PRWEB) , ... February 16, 2017 , ... ... cervical case. Dr. Kingsley Chin, professor and Harvard trained surgeon, completed the procedure ... was performed on a 55-year-old practicing female physician suffering from degenerative disc disease ...
(Date:2/16/2017)... ... February 16, 2017 , ... ... industry leading Biochemistry Services specifically targeting the rapidly growing needs of the ... the biochemical and biosimilar characterization , product-related impurity characterization, aggregation ...
Breaking Biology Technology:
(Date:1/18/2017)... Md. , Jan. 18, 2017  In vitro ... respect to mergers and acquisitions (M&A), and Kalorama Information ... for such acquisitions have been shifting. Generally, uncertainty in ... and the U.S. has changed the acquisitions landscape. ... has resulted in companies buying partners outside of their ...
(Date:1/13/2017)... , Jan. 13, 2017 Sandata ... solutions for the homecare industry, including Electronic Visit ... industry expert, Justin Jugs, as Senior Vice President ... than 15 years of homecare experience to Sandata, ... developing strategic plans to align Sandata,s suite of ...
(Date:1/12/2017)... research undertaken by Fit Small Business has revealed ... simply asked which office technology had they not used in ... Insights on what will be key features in ... industry leaders including Penelope Trunk , Martin Lindstrom ... Some of these findings included; ...
Breaking Biology News(10 mins):